LONDON/BANGKOK — Healthcare workers in Britain and Thailand have started taking part in a trial to determine whether two anti-malarial drugs can prevent COVID-19, including one that U.S. President Donald Trump says he has been taking.
The study, involving more than 40,000 healthcare workers across Europe, Africa, Asia and South America, seeks to determine whether chloroquine and hydroxychloroquine could play a role in the fight against the novel coronavirus.
Demand for hydroxychloroquine surged after Trump touted it in early April. He said this week he was now taking it as a preventive medicine against the virus despite medical warnings about its use.
The lead investigators in Thailand and Britain said their ‘COPCOV’ trial, in the works for several months, would cut through the heated and unhelpful debate.
Story continues below advertisement
“We still do not know whether anything is beneficial in COVID-19,” the University of Oxford’s Professor Nicholas White, the study’s co-principal investigator, told Reuters.
“The only way we can find out if things are beneficial overall is to do large, well-conducted clinical trials,” said White, who is based at the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok.